Mostrar el registro sencillo del ítem

dc.contributor.authorCuellar-Valencia L
dc.contributor.authorClaros-Hulbert A
dc.contributor.authorOrtegon A
dc.contributor.authorPino J
dc.contributor.authorVelandia L
dc.contributor.authorCorrea-Morales J.E.
dc.date.accessioned2024-10-07T21:39:24Z
dc.date.available2024-10-07T21:39:24Z
dc.date.issued2024
dc.identifier.issn10499091
dc.identifier.otherhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85175612709&doi=10.1177%2f10499091231212450&partnerID=40&md5=9a4069dbe9bc4ec78e1b1b28c4e671ea
dc.identifier.urihttp://hdl.handle.net/10818/61902
dc.description.abstractBackground: Levetiracetam has a favorable pharmacology profile to be used subcutaneously. However, its subcutaneous use is still considered off-label as this is beyond its license. The evidence base for its safety, tolerability, and efficacy is limited to observational studies. Objectives: To report the safety and efficacy of subcutaneous levetiracetam in Latino patients on home care. Design: Observational retrospective case series study. Subjects: Consecutive sample of Latino adults with life-limiting illnesses. Methods: A case series framework with 4 domains (selection, ascertainment, causality, and reporting) to ensure reporting quality was used. Additionally, 8 relevant outcomes established in a previous comprehensive review, were collected and reported. Adverse reactions were documented using the Common Terminology Criteria for Adverse Events. Results: Fifteen Latino patients with oncological and non-oncological diagnoses received subcutaneous levetiracetam for a mean of 21 days on home care. Levetiracetam was most frequently initiated subcutaneously due to loss of the oral route. The average dosage of subcutaneous levetiracetam was 1200 mg. Only 1 patient required a dose adjustment, and only 2 patients experienced a total of 5 seizures during the therapy trial. No adverse reactions were reported. Conclusions: Subcutaneous levetiracetam appears to be effective and safe. This case series of Latino patients in home care expands the evidence of its use in the home care setting. The preliminary data reported by now on multiple case series warrants robust trials. © The Author(s) 2023.en
dc.formatapplication/pdfes_CO
dc.language.isoenges_CO
dc.publisherAmerican Journal of Hospice and Palliative Medicinees_CO
dc.relation.ispartofseriesAmerican Journal of Hospice and Palliative Medicine Vol. 41 N° 9
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceUniversidad de La Sabanaes_CO
dc.sourceIntellectum Repositorio Universidad de La Sabanaes_CO
dc.subject.otherhome careen
dc.subject.otherlevetiracetamen
dc.subject.otherpalliative careen
dc.subject.otherseizureen
dc.subject.othersubcutaneousen
dc.titleSubcutaneous Levetiracetam Administration in Latino Patients on Home Careen
dc.typejournal articlees_CO
dc.type.hasVersionpublishedVersiones_CO
dc.rights.accessRightsopenAccesses_CO
dc.identifier.doi10.1177/10499091231212450


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International